Dear Editor, This letter describes an innovative pilot project providing community outreach education to preschool children about the dangers of cigarette smoking. Arkansas youth use tobacco at higher rates compared to the US youth smoking rate, which has significantly declined in recent years 1. The initiation of cigarette smoking during childhood and adolescent years increases the risk of lifelong nicotine dependence. Education efforts aimed at empowering youth to say no to smoking have the potential to affect health outcomes 2. Lower socioeconomic status and lower education levels are risk factors correlated to high smoking prevalence 3. Government-funded Head Start Programs provide education and other assistance to low-income preschool children and their families. The purpose of the pilot study was to examine the impact of a brief educational program on the hazards of cigarette smoking in preschool children, aged 3-5 years, enrolled in Arkansas Head Start Programs. The study was approved by the Institutional Review Board. It was funded by the Arkansas Cancer Coalition and completed at select Arkansas Head Start Program facilities located in rural areas of central Arkansas. The pre-post study design was used to evaluate the effectiveness of the educational program. Under the supervision of a pharmacist faculty, a team of third-year pharmacy students delivered a brief multi-modal interactive educational program on the hazards of cigarette smoking. An illustration of a healthy versus a rotten apple was used to explain the difference between a healthy lung and a lung exposed to cigarette smoke. A respiratory system model provided a hands-on learning experience demonstrating the differences in the elastic recoil of a healthy versus a damaged lung. An anatomical model of a buccal cavity was also used to demonstrate the damage of cigarette smoke on teeth and mouth. Assessment of understanding took place before and after the education program by asking participants to raise their hands if they thought smoking was bad for their health. During two months, the team traveled to five Head Start locations in three counties of central Arkansas. Ninety-two preschool children's responses were collected. The pre and post responses indicated an increase of knowledge. Fifty-seven (61%) children knew that smoking was harmful to a person's health before program delivery compared to 78 (84%) children after education. This pilot study describes a collaborative effort between an academic setting and a government-funded program to deliver smoking prevention education to a preschool audience. The children's improved knowledge about the dangers of smoking from the intervention could empower them to avoid cigarette smoke in their lives. Limitations of the pilot study include the rural location, short period, and small sample size. A study of longer duration with larger sample size AFFILIATION

Three new drugs are presented: dostarlimab, loncastuximab tesirine, and aducanumab. Product information, clinical trials, and recommendations are provided. Dostarlimab (Jemperli®) is FDA-indicated for the treatment of adult patients with mismatch repair deficient (dMMR - an abnormality that affects DNA repair) recurrent or advanced endometrial cancer (EC). Loncastuximab tesirine (Zynlonta®) is FDA-indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma. Aducanumab (Aduhelm®) is FDA-indicated for the treatment of Alzheimer’s disease. It is an amyloid beta-directed antibody developed by Biogen of Cambridge, Massachusetts. This indication was approved on June 7, 2021, under the accelerated approval based on the reduction in amyloid beta plaques in patients treated with the drug.

No abstract

Background: Pharmacist clinical intervention is defined as the action that identifies and prevents medication-related problems

Three drugs are discussed in this article: finerenone, difelikefalin, and avacopan. Finerenone (Kerendia™) is FDA-indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease (ESKD), cardiovascular (CV) death, non-fatal myocardial infarction (MI), and hospitalization for heart failure (HF) in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Difelikefalin (Korsuva™) is FDA-indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Avacopan (Tavneos™) is FDA-indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids.